Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial.
Yue D, Wang W, Liu H, Chen Q, Chen C, Liu L, Zhang P, Zhao G, Yang F, Han G, Cheng Y, Yu B, Yang Y, Chen H, Jiang J, Tan L, Xu S, Mao N, Hu J, Zhang L, Yao B, Wang S, Wang RH, Zheng W, Wang C; RATIONALE-315 investigators.
Yue D, et al. Among authors: wang w.
Lancet Respir Med. 2024 Nov 21:S2213-2600(24)00269-8. doi: 10.1016/S2213-2600(24)00269-8. Online ahead of print.
Lancet Respir Med. 2024.
PMID: 39581197